Easy NAPLEX Antiviral Practice Questions

Concept Explanation

NAPLEX antiviral medications are therapeutic agents designed to inhibit the replication of viruses by targeting specific stages of the viral life cycle, such as attachment, entry, uncoating, synthesis of viral components, or release. Mastery of these drugs is essential for the NAPLEX Prep process, as clinicians must understand the mechanisms of action, dosing requirements, and potential side effects for common viral infections including herpes simplex, varicella-zoster, influenza, and HIV.

Antivirals are generally classified based on the virus they treat. For example, acyclovir is a guanosine analog that requires phosphorylation by viral thymidine kinase to inhibit viral DNA polymerase, effectively halting DNA chain elongation in herpes viruses. Other classes, such as neuraminidase inhibitors (e.g., oseltamivir), prevent the release of influenza virus from infected cells. Understanding these pathways is crucial for clinical decision-making. You can further refine your study strategy by utilizing our AI MasterPlan to organize your review of these pharmacology topics.

Solved Examples

1. Question: A 45-year-old patient presents with shingles. Which of the following is the preferred dosing regimen for acyclovir in a patient with normal renal function?
   Solution: Acyclovir for herpes zoster (shingles) is typically dosed at 800 mg five times daily for 7 to 10 days. The correct answer is 800 mg PO five times daily.
2. Question: An elderly patient is prescribed oseltamivir for influenza. What is the standard duration of treatment for uncomplicated influenza in adults?
   Solution: Oseltamivir is typically administered as 75 mg PO BID for 5 days. The standard duration is 5 days.
3. Question: A patient with a history of HIV is starting a new regimen. Which class of antiretrovirals is known for potentially causing a hypersensitivity reaction requiring HLA-B*5701 testing?
   Solution: Abacavir is the specific agent associated with a high risk of hypersensitivity reactions in patients carrying the HLA-B*5701 allele. Testing is mandatory before initiation.

Practice Questions

1. Which of the following medications is a prodrug of acyclovir with improved oral bioavailability?
2. A patient with HSV-1 labialis should be treated with which of the following for episodic therapy?
3. Valganciclovir is primarily indicated for the treatment of which viral infection in transplant recipients?

4. Which antiviral agent is associated with potential bone marrow suppression, particularly neutropenia?
5. What is the primary mechanism of action of oseltamivir?
6. Which medication requires the administration of probenecid to increase its plasma concentration?
7. For a patient with CrCl <$50$ mL/min, which of the following adjustments is necessary for acyclovir?
8. Which class of HIV medications is associated with a risk of fat redistribution (lipodystrophy)?

Answers & Explanations

1. Valacyclovir: Valacyclovir is the L-valyl ester prodrug of acyclovir, which provides higher plasma concentrations compared to oral acyclovir.
2. Valacyclovir (2g BID for 1 day): This is the standard high-dose, short-course regimen for episodic treatment of herpes labialis.
3. Cytomegalovirus (CMV): Valganciclovir is the prodrug of ganciclovir and is used for the treatment and prophylaxis of CMV disease.
4. Ganciclovir/Valganciclovir: These agents are known for dose-dependent bone marrow suppression, notably neutropenia and thrombocytopenia. Clinical resources provide detailed monitoring guidelines.
5. Neuraminidase inhibitor: Oseltamivir inhibits the viral neuraminidase enzyme, preventing the release of new viral particles from the surface of infected cells.
6. Cidofovir: Probenecid is administered with cidofovir to reduce the risk of nephrotoxicity by blocking its renal tubular secretion.
7. Dose reduction and/or frequency adjustment: Acyclovir is renally cleared; therefore, dosage intervals must be extended or doses reduced based on the patient's creatinine clearance.
8. Protease Inhibitors (PIs): PIs are frequently associated with metabolic side effects, including hyperglycemia, dyslipidemia, and lipodystrophy.

1. Which agent is the prodrug of ganciclovir?

• AAcyclovir
• BValacyclovir
• CValganciclovir
• DFamciclovir

Frequently Asked Questions

What is the clinical significance of HLA-B*5701 testing in HIV patients?

HLA-B*5701 testing is a mandatory screening test before starting Abacavir to identify patients at high risk for a severe, potentially fatal hypersensitivity reaction. If a patient tests positive, Abacavir should never be initiated.

How does renal impairment affect acyclovir dosing?

Acyclovir is primarily eliminated through the kidneys; therefore, patients with reduced creatinine clearance require lower doses or longer dosing intervals to prevent drug accumulation and neurotoxicity. Clinicians should refer to standardized CDC or FDA prescribing guidelines for specific adjustments.

Why is valacyclovir preferred over acyclovir for oral administration?

Valacyclovir has significantly better oral bioavailability than acyclovir, allowing for less frequent dosing schedules. This improvement in patient adherence is a major factor in choosing valacyclovir for chronic suppressive therapy.

What is the maximum duration for oseltamivir treatment in uncomplicated influenza?

The standard course of treatment for uncomplicated influenza with oseltamivir is 5 days. Extending therapy beyond this duration is generally not recommended unless the patient is severely immunocompromised or hospitalized.

Are there specific monitoring parameters for ganciclovir?

Ganciclovir therapy requires regular monitoring of complete blood counts (CBC) to detect potential neutropenia or thrombocytopenia. Additionally, renal function must be monitored closely due to the risk of nephrotoxicity.